Other At-Risk Groups GLP-1 medications are generally not suitable for individuals with severe gastrointestinal disorders like gastroparesis, those with type 1 diabetes (as these drugs are approved only for type 2 diabetes and obesity), and people with a history of suicidal thoughts, active eating disorders, or heavy alcohol use
Initially, you may start with a lower dose to minimize potential side effects, such as nausea, and gradually increase the dosage over time as your body adjusts to the medication
At the beginning of this study there were no reported transcript sequences for these genes and some of the genomic sequences were incomplete
Following the publication of the guidelines, criticism and questions have emerged
Patients in the study were receiving dulaglutide (7), semaglutide injection (27), semaglutide oral (3), and tirzepatide (23)
That said, medication is never the whole story